Safety Warning - BORTEZOMIB

March 13, 2018

On November 6, 2017, Fresenius Kabi USA, LLC received FDA approval for its product, BORTEZOMIB for Injection. BORTEZOMIB for injection is indicated for the treatment of patients with multiple myeloma and the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy. As a committed partner in the fight against multiple myeloma and mantle cell lymphoma, Takeda Oncology welcomes the availability of a different formulation of bortezomib for patients who need access to additional options. For more information, please click here.

Share on Facebook
Share on Twitter
Please reload

Featured Posts

AVAHO President's Farewell

December 14, 2018

1/4
Please reload

Recent Posts

December 14, 2018

March 7, 2018

Please reload

Archive
Please reload

Search By Tags

I'm busy working on my blog posts. Watch this space!

Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square